Funda Meric-Bernstam, MD
Department of Investigational Cancer Therapeutics, Division of Cancer Medicine
Present Title & Affiliation
Primary Appointment
Endowed Chair Nellie B. Connally Chair in Breast Cancer, Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX
Department Chair, Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX
Medical Director, Khalifa Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX
Professor, Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Regular Member (Joint appointment), Cancer Biology, University of Texas Houston Graduate School of Biomedical Sciences, Houston, TX
Dual/Joint/Adjunct Appointment
Nellie B. Connally Chair in Breast Cancer, Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX
Professor, Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Regular Member, Cancer Biology, University of Texas Houston Graduate School of Biomedical Sciences, Houston, TX
Research Interests
Funda Meric-Bernstam is the Chair of the Department of Investigational Cancer Therapeutics -- the Phase I Program, and the Medical Director of the Institute for Personalized Cancer Therapy at MD Anderson Cancer Center. She has a basic and translational research program that is focused on molecular therapeutics, to delineate the mechanism of action of each agent targeting this pathway and the molecular alterations useful to prospectively identify patients who will benefit most from each agent, and optimal combination therapies with targeted therapies and novel immune-modulators. She is an active clinical trialist focused on Phase I trials, and rationale combinations, biomarker-driven therapy and immune-oncology.
Education & Training
Degree-Granting Education
| 1991 | Yale University School of Medicine, New Haven, Connecticut, US, MD |
Postgraduate Training
| 1999-2000 | Research Fellowship, Molecular Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 1998-2001 | Fellow, Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 1996-1998 | Resident, General Surgery, University of Michigan Medical Center, Ann Arbor, Michigan |
| 1994-1996 | Postdoc Fellow, Regulation of Gene Expression, National Institute of Health, Bethesda, Maryland |
| 1991-1994 | Resident, General Surgery, University of Michigan Medical Center, Ann Arbor, Michigan |
Licenses & Certifications
| 2015 | American Board of Preventive Medicine (ABPM); Subspecialty Clinical Informatics |
| 1999 | American Board of Surgery |
| 1999 | DEA |
| 1999 | Texas Medical Board |
| 1999 | Texas Department of Public Safety |
Experience & Service
Administrative Appointments/Responsibilities
Department Chair, Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, 2013 - Present
Medical Director, Khalifa Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, 2011 - Present
Other Professional Positions
Advisory Committee, Single-Cell Multi-omics Study on TROP2-ADC Response, UT MD Anderson, 2025 - Present
REJOICE-Ovarian01 Data Monitoring Committee, Clinical Trial, Daiichi Sankyo, Inc, 2025 - 2029
TAPUR Scientific Advisory Group, American Society of Clinical Oncology, 2025 - 2027
TBCRC EVOLVE Trial External Advisory Board, Lineberger Comprehensive Cancer Center, 2025 - 2031
MD Anderson Site Director, UT Health Clinical Informatics Fellowship Program, Houston, TX, 2023
Scientific Committee, 32nd EORTC-NCI-AACR Symposium, EORTC-NCI-AACR, Barcelona, 2020
Co-Chair, NCI, Special Emphasis Panel, U01 Grant Applications, Novel Technology Tools to Facilitate Research Using Next Generation Patient-derived Cancer Models, Rockville, MD, 2019
Member, Targeted Agent and Profiling Utilization Registry (TAPUR) Study Steering Group, American Society of Clinical Oncology, Alexandria, VA, 2019
Chair, NCI ComboMATCH Steering Committee and Agents and Genes Working Group, Houston, TX, 2019 - Present
Member, Patient Derived Xenograft Network Clinical Translation Committee, Houston, TX, 2019 - Present
ASCO-Friends-FDA Planning Committee, ASCO, Alexandria, VA, 2018
External Reviewer, NCI National Clinical Trials Network Biospecimen Banks (NCTN Banks), NIH/NCI, Rockville, MD, 2018
Member, ESMO Translational Research and Personalized Medicine Working Group, Lugano, 2018
Co-Chair, Expert panel charged with the development of a Somatic Genetic Panel Testing for Metastatic Disease Guideline, ASCO, Chicago, IL, 2018
NCI T32 External Advisor, Johns Hopkins, Baltimore, MD, 2017 - Present
Chair, Internal Advisory Committee, NCI T32 Multidisciplinary Subspecialty Pathology, MD Anderson Cancer Center, Houston, TX, 2017 - Present
NCI T32 External Advisor, Surgical Oncology, University of Alabama at Birmingham School of Medicine, Birmingham, AL, 2016 - Present
Member, NCI-CCCT Investigational Drug Steering Committee, Bethesda, MD, 2014 - Present
NCI-MATCH Agent and Gene Selection Working Group, NIH/NCI, Bethesda, MD, 2014 - Present
NCI T32 External Advisor, Cancer Biology, University of Kentucky, Lexington, KY, 2013 - Present
Advisory Board, NCI T32 Internal Advisory Board, Medical Oncology and Hematology and GYN Oncology, MD Anderson Cancer Center, Houston, TX, 2012 - Present
Associate Member, Komen for the Cure Scientific Advisory Council, Washington, DC, 2010 - Present
Member Locoregional Disease Working Group, Translational Breast Cancer Research Consortium, Rockville, MD, 2009 - Present
Member, TCGA Breast Working Group, NCI, Bethesda, MD, 2009 - Present
Alternate Correlative Studies Working Group Liaison to the Locoregional Disease Working Group, Translational Breast Cancer Research Consortium Correlative Science Working Group, Rockville, MD, 2009 - Present
Extramural Institutional Committee Activities
Co-Chair, IDSC, National Cancer Institute/National Institutes of Health, 2025 - Present
Executive Committee Member, NCTN LAPS Grant Executive Committee, The University of Texas MD Anderson Cancer Center, 2020 - Present
Member, Breast Cancer Program Steering Committee, The University of Texas MD Anderson Cancer Center, 2014 - Present
Member, Molecular Testing Evaluation Committee, The University of Texas MD Anderson Cancer Center, 2011 - Present
Associate Member, Institutional Review Board (IRB5), The University of Texas MD Anderson Cancer Center, 2008 - Present
Member, Physician Scientist Review Committee, The University of Texas MD Anderson Cancer Center, 2007 - Present
Editorial Activities
Editorial Board, Annals of Oncology, 2024 - Present
Editor, www.personalizedcancertherapy.org, 2014 - Present
Editorial Board Member, Translation, 2012 - Present
Honors & Awards
| 2025 | Castle Connolly Top Doctor, Castle Connolly |
| 2025 | Exceptional Women in Medicine, Castle Connolly |
| 2024 - Present | James Ewing Lecturer Award, Society of Surgical Oncology |
| 2024 | Castle Connolly Top Doctor, Castle Connolly |
| 2024 | Exceptional Women in Medicine, Castle Connolly |
| 2024 | TAT Honorary Award, ESMO |
| 2023 | Flance-Karl Award, American Surgical Association |
| 2023 | Exceptional Women in Medicine, Castle Connolly |
| 2022 | Exceptional Women in Medicine, Castle Connolly |
| 2021 | Exceptional Women in Medicine, Castle Connolly |
| 2020 | Division of Cancer Medicine Faculty Recognition for Fastest Protocol Timelines, MD Anderson Cancer Center |
| 2020 | Exceptional Women in Medicine, Castle Connolly |
| 2019 - 2023 | Highly Cited Researcher, Web of Science |
| 2019 | Exceptional Women in Medicine, Castle Connolly |
| 2017 | MD Anderson Cancer Center, Top Performer (Nationally on CAHPS Measures Related to Patient Care) |
| 2017 | Alcides & Rosaura Diniz (ARD) Foundation Excellence in Oncology Award, Alcides & Rosaura Diniz Foundation |
| 2015 - 2018 | Advisor (and Komen representative, CancerLinQ (CLQ) Data Governance Oversight Committee, CancerLinQ LLC/ASCO |
| 2015 | American Society for Clinical Investigation |
| 2011 | America's Top Doctor for Cancer, Castle Connolly |
| 2009 - 2011 | Clinical Investigator Award in Breast Cancer Research, Society of Surgical Oncology |
| 2009 - 2010 | Society of Surgical Oncology Clinical Investigator Award in Breast Cancer Research, Susan O. Komen |
| 2005 | Outstanding Teaching Award for Research, M. D. Anderson Cancer Center, Department of Surgical Oncology |
| 2001 | Career Development Award (returned due to scientific overlap with K08), United States Department of Defense |
| 2000 - 2001 | Administrative Fellow, M.D. Anderson Dept. of Surgical Oncology |
| 1999 | ASCO-Kanojia Award, M. D. Anderson Associates |
| 1999 | Clinical Fellows Research Award, M.D. Anderson Associates |
| 1997 | Young Investigator Award, University of Michigan, Department of Surgery |
| 1996 | NIH Fellows Award for Research Excellence, National Institutes of Health |
| 1994 - 1996 | NIH Intramural National Research Service Award, National Institutes of Health |
| 1991 | Janet M. Glasgow Memorial Achievement Citation, Yale University School of Medicine |
| 1991 | Alpha Omega Alpha, Honor Medical Society |
| 1991 | Connecticut Society of American Board Surgeons Prize, Yale University School of Medicine |
| 1991 | Doctor of Medicine Cum Laude, Yale University School of Medicine |
| 1988 | Summer Research Fellowship, Yale University School of Medicine |
| 1984 - 1987 | Dogramaci Scholarship, Turkey |
| 1983 - 1987 | Koc Scholarship, Turkey |
| 1983 | Highest Scientific Test Score (First-Prize) - Turkish University Entrance Exams |
Professional Memberships
Selected Presentations & Talks
Local Presentations
- 2025. Evolving strategies in antibody drug conjugate therapy. Invited. 2nd Joint Symposium on Cancer Biology & Precision Oncology. Houston, Texas, US.
- 2025. Genomically informed therapy: Advances and informatics challenges. Invited. UT Health Houston, McWilliams School of Biomedical Informatics. Houston, Texas, US.
- 2025. Tumor Agnostics. Invited. 2025 Fall Conference on Advances in Oncology. Houston, Texas, US.
- 2024. Navigating the NCI’s Early Therapeutics Clinical Trials Network. Conference. Navigating the NCI’s Early Therapeutics Clinical Trials Network. Houston, TX, US.
- 2023. Panel Discussion on Targeted Delivery of Tumor Killing Agents ADCs and RLTs. Conference. Panel Discussion on Targeted Delivery of Tumor Killing Agents ADCs and RLTs. Houston, TX, US.
- 2022. Implementing Precision Oncology. Visiting. Houston Methodist Oncology Grand Rounds,. Houston, TX, US.
- 2019. Personalizing the Treatment of Cancer. Conference. Personalizing the Treatment of Cancer. Houston, TX, US.
- 2019. Decision Support for Precision Oncology. Conference. Decision Support for Precision Oncology. Houston, TX, US.
- 2019. Personalized (precision) medicine: A primer for oncology nurses. Conference. Personalized (precision) medicine: A primer for oncology nurses. Houston, TX, US.
- 2015. Genomic Resources for Clinical Trials. Conference. Genomic Resources for Clinical Trials. Houston, TX, US.
- 2014. Clinical Trials Phase 1 End of Year Summary and Vision for 2014. Conference. Clinical Trials Phase 1 End of Year Summary and Vision for 2014. Houston, TX, US.
- 2013. Cancer Genomics. Conference. Cancer Genomics. Houston, TX, US.
- 2013. Challenging cases in Breast cancer management. Conference. Challenging cases in Breast cancer management. Houston, TX, US.
- 2013. Emerging treatments and advances in metastatic breast cancer. Conference. Emerging treatments and advances in metastatic breast cancer. Houston, TX, US.
- 2013. Institute of Personalized Cancer Therapy Molecular Testing Program. Conference. Institute of Personalized Cancer Therapy Molecular Testing Program. Houston, TX, US.
- 2012. Biobanking and Tissue Based Research: Clinical and Ethical Concerns. Conference. Biobanking and Tissue Based Research: Clinical and Ethical Concerns. Houston, TX, US.
- 2012. Informatics to enable personalized cancer care. Conference. Informatics to enable personalized cancer care. Houston, TX, US.
- 2011. Best Science: Advances in Breast Cancer Treatment and Research. Conference. Best Science: Advances in Breast Cancer Treatment and Research. Houston, TX, US.
- 2010. PI3K/mTOR Signaling as a Therapeutic Target: Opportunities for Nanotechnology. Conference. PI3K/mTOR Signaling as a Therapeutic Target: Opportunities for Nanotechnology. Houston, TX, US.
- 2009. mTOR signaling as a target for cancer therapy. Conference. mTOR signaling as a target for cancer therapy. Houston, TX, US.
- 2008. Towards Personalized Breast Cancer Therapy. Conference. Towards Personalized Breast Cancer Therapy. Houston, TX, US.
- 2008. Targeting mTOR: From Bench to Bedside and Back. Conference. Targeting mTOR: From Bench to Bedside and Back. Houston, TX, US.
- 2008. Breast Cancer. Conference. Breast Cancer. Houston, TX, US.
- 2007. Pathologic Nodal Status for clinical T3NO Breast Cancer. Conference. Pathologic Nodal Status for clinical T3NO Breast Cancer. Houston, TX, US.
- 2007. The Principles of Molecular Therapeutics. Conference. The Principles of Molecular Therapeutics. Houston, TX, US.
- 2007. The Principles of Molecular Therapeutics. Conference. The Principles of Molecular Therapeutics. Houston, TX, US.
- 2007. The Successful Academic Career - Senior Faculty Share their tips on academic success. Conference. The Successful Academic Career - Senior Faculty Share their tips on academic success. Houston, TX, US.
- 2005. Breast Cancer Biomarkers. Conference. Breast Cancer Biomarkers. Houston, TX, US.
- 2005. Introduction to Biomarkers. Conference. Introduction to Biomarkers. Houston, TX, US.
- 2005. Lymphatic Mapping in Breast Cancer. Conference. Lymphatic Mapping in Breast Cancer. Houston, TX, US.
- 2002. Bioinformatics Tools and Applications (Informatics Short Course). Conference. Bioinformatics Tools and Applications (Informatics Short Course). Houston, TX, US.
- 2001. Breast Cancer Research. Conference. Breast Cancer Research. Houston, TX, US.
Regional Presentations
- 2025. Drug Discovery & Development. Conference. Texas Regional CTSA Consortium. San Antonio, TX, US.
- 2020. Genomic Tumor Board: Opportunities and Pitfalls. Conference. Genomic Tumor Board: Opportunities and Pitfalls. San Antonio, TX, US.
- 2019. Precision Oncology Decision Support Core: Update on CPRIT-funded Core Facility Research. Conference. Precision Oncology Decision Support Core: Update on CPRIT-funded Core Facility Research. Austin, TX, US.
- 2017. DEBATE: This house believes that all women diagnosed with metastatic breast cancer should undergo next generation sequencing?. Conference. DEBATE: This house believes that all women diagnosed with metastatic breast cancer should undergo next generation sequencing?. San Antonio, TX, US.
- 2017. Precision Oncology Decision Support Core: Update on CPRIT-funded Core Facility Research. Conference. Precision Oncology Decision Support Core: Update on CPRIT-funded Core Facility Research. Austin, TX, US.
- 2017. Bench to Bedside. Conference. Bench to Bedside. Galveston, TX, US.
- 2014. ConvertHER: Evolution of Genomic Alterations from Primary to Metastatic Breast Cancer. Conference. ConvertHER: Evolution of Genomic Alterations from Primary to Metastatic Breast Cancer. San Antonio, TX, US.
- 2011. Best Science. Conference. Best Science. Fort Worth, TX, US.
- 2009. Translational Research in Breast Surgical Oncology. Conference. Translational Research in Breast Surgical Oncology, US.
- 2009. Phase II randomized study of ixabepilone vs. observation in patients with significant residual disease after neoadjuvant systemic therapy for HER2/neu-negative breast cancer. Conference. Phase II randomized study of ixabepilone vs. observation in patients with significant residual disease after neoadjuvant systemic therapy for HER2/neu-negative breast cancer. San Antonio, TX, US.
- 2005. Progress in Breast Cancer Therapy. Conference. Progress in Breast Cancer Therapy. Austin, TX, US.
National Presentations
- 2026. Clinical Advances in HER2-Directed Therapy. Invited. ICRN/ENS-CCA Translational Science Seminar Series. Virtual, US.
- 2026. Improving triple negative breast cancer with personalised PARP inhibitor- based combination therapy. Invited. SU2C Scientific Summit 2026. Pasadena, California, US.
- 2026. Matching Novel Drug Delivery Systems to Actionable Targets. Invited. 22nd Oncology Updates: Advanced and Controversies. Steamboat Springs, Colorado, US.
- 2025. ADCs for pancreatic cancer. Invited. AACR Special Conference on Pancreatic Cancer. Boston, MA, US.
- 2025. Optimizing therapy with antibody drug conjugates. Invited. ASCI Scientific Session, US.
- 2025. Exciting New Therapies on the Horizon. Invited. PER's International Congress on the Future of Breast Cancer. San Diego, CA, US.
- 2025. Advances in Personalized Cancer Therapy. Invited. Dartmouth Cancer Center Grand Rounds. Dartmouth, MA, US.
- 2025. Bispecifics Plus Tyrosine Kinase Inhibition in Combination Strategy. Invited. ASCO Annual Meeting. Chicago, IL, US.
- 2025. Targeting HER2 for Cancer Therapy: Clinical Advances and Pathology Considerations. Invited. University of Southern California, Dept. of Pathology Grand Rounds, US.
- 2025. Clinical application of transcriptomics in precision oncology. Invited. AAADV Workshop, US.
- 2025. An open-label, multicenter, Phase 2 study of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) Part 2. Poster. AACR Annual Meeting, US.
- 2025. Translational Science Working Group. Conference. Cholangiocarcinoma Foundation Annual Conference. Salt Lake City, UT, US.
- 2025. Automating Patient Matching to Clinical Trials. Invited. GA4GH Connect, US.
- 2025. Advances in Treatment with Antibody-drug Conjugates. Invited. MSK Early Drug Development Service Scientific Meeting, US.
- 2025. HER2 Antibody-Drug Conjugate Therapy: A New Frontier in Bladder Cancer. Invited. ASCO Genitourinary Cancers Symposium. San Francisco, CA, US.
- 2025. Datopotamab deruxtecan (Dato-DXd) in locally advanced/metastatic urothelial cancer: Updated results from the phase 1 TROPIONPanTumor01 study. Conference. ASCO Genitourinary Cancers Symposium. San Francisco, CA, US.
- 2025. Promising Actional Target from 2024. Conference. 21 Oncology Update. Steamboat Springs, CO, US.
- 2024. Guidelines for Genomic Testing Today. Conference. NASEM Workshop - Examining Clinical Guidelines for the Adoption of Genomic Testing. Washington, DC, US.
- 2024. ADCs: Patient Selection and Novel Combinations. Invited. 2024 Ochsner Multidisciplinary Cancer Update. New Orleans, LA, US.
- 2024. Emerging ADC Clinical Data. Invited. Immunomodulation of ADCs Virtual Summit, US.
- 2024. Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing head and neck tumors: Outcomes from DESTINY-PanTumor02 (DP-02). Poster. ASCO Annual Meeting. Chicago, Illinois, US.
- 2024. Pertuzumab plus trastuzumab (P+T) in patients (pts) with solid tumors with ERBB2 or ERBB3 amplification (amp) or mutations (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study. Poster. ASCO Annual Meeting. Chicago, Illinois, US.
- 2024. Implementing Precision Oncology. Visiting. 26th Annual George E. Block Memorial Lecture. Chicago, Illinois, US.
- 2024. Implementing Precision Oncology. Visiting. Masters of Surgery Grand Rounds Presentation. Bronx, New York, US.
- 2024. In Vivo Modeling and Considerations for Clinical Translation. Conference. In Vivo Modeling and Considerations for Clinical Translation. Salt Lake City, UT, US.
- 2024. TIP Poster Presentation: An open-label phase 1 study to investigate SGN-CEACAM5C in adults with advanced solid tumors (SGNCEA5C-001, Trial in Progress). Conference. Seagen. San Diego, CA, US.
- 2024. James Ewing Featured Lecturer. Conference. James Ewing Featured Lecturer. Atlanta, GA, US.
- 2024. Implementing Precision Oncology. Visiting. Medical Oncology Grand Rounds. St. Louis, MO, US.
- 2024. Biomarker Directed Conjugate Therapy and Promising Actional Targets. Conference. 20th Oncology Update. Steamboat Spring, CO, US.
- 2023. Optimizing Personalized Cancer Therapy. Invited. Perlmuter Cancer Center Research Seminar Series. New York, NY, US.
- 2023. Poster Presentation: TROPION-PanTumor03: Phase 2, multicenter study of datopotamab deruxtecan (Dato-DXd) as monotherapy and in combination with anticancer agents in patients (pts) with advanced/metastatic solid tumors. Conference. AACR Annual Meeting. Orlando, FL, US.
- 2023. AACR Dinner Symposium: Therapeutics Targeting TROP-2 and HER3: Perspective on the Next Precision Treatment Advances Across Solid Tumors. Conference. AACR Dinner Symposium: Therapeutics Targeting TROP-2 and HER3: Perspective on the Next Precision Treatment Advances Across Solid Tumors. Orlando, FL, US.
- 2023. Management of Futibatinib-Associated Adverse Events in Patients With Advanced Cancers: Results of a Pooled Analysis. Conference. Taiho Oncology. Salt Lake City, UT, US.
- 2023. The Future of Antibody Drug Conjugates and Selective PIK3CA-Pathway Inhibitors. Conference. 19th Oncology Update: Advances and Controversies. Steamboat Springs, CO, US.
- 2022. Spotlight Poster: Phase 1 TROPION-PanTumor01 Study Evaluating Datopotamab Deruxtecan (Dato-DXd) in Unresectable or Metastatic Hormone Receptor–Positive/HER2–Negative Breast Cancer (BC). Conference. San Antonio Breast Cancer Symposium (SABCS). San Antonio, TX, US.
- 2022. Delving into Patient selection for HER2 targeted Basket Trials. Conference. HER2 Targeted Therapies Summit. Boston, MA, US.
- 2022. Safety and clinical activity of single-agent ZN-c3, an oral WEE1 inhibitor, in a phase 1 trial in subjects with recurrent or advanced uterine serous carcinoma (USC). Conference. AACR Annual Meeting. New Orleans, LA, US.
- 2022. Translational Research with Patient-Derived Models: Bench to Bedside and Back. Visiting. William A Maddox Visiting Professor. Birmingham, AL, US.
- 2022. Informatics Challenges in Precision Oncology. Visiting. Biomedical Informatics Grand Rounds. Salt Lake City, Utah, US.
- 2021. Poster Presentation: A phase II, multicenter, open-label study evaluating trastuzumab deruxtecan (T-DXd) for the treatment of select HER2-expressing solid tumors (DESTINY-PanTumor02). Conference. ESMO Congress, US.
- 2021. Poster Presentation: Pooled analysis safety profile of futibatinib in patients with advanced solid tumors, including intrahepatic cholangiocarcinoma (iCCA). Conference. ESMO Congress, US.
- 2021. Progress in Precision Oncology. Invited. Seattle, Washington, US.
- 2021. Oral Abstract: Clinical activity of single-agent ZN-c3, an oral WEE1 inhibitor, in a phase 1 dose-escalation trial in patients with advanced solid tumors. Conference. AACR Annual Meeting, US.
- 2021. Poster Presentation: A systematic review of the tumor growth metrics of patient-derived xenograft (PDX) models in the literature and in NCI PDXNet centers. Conference. AACR Annual Meeting, US.
- 2021. Oral Abstract: Efficacy of atezolizumab in the treatment of solid tumors with high tumor mutational burden (TMB): A MyPathway study cohort. Conference. AACR Annual Meeting, US.
- 2021. Modeling acquired resistance and underlying mechanisms in cancer therapy. Conference. Modeling acquired resistance and underlying mechanisms in cancer therapy, US.
- 2021. Webinar: HER2-targeted therapies in CCA. Conference. Webinar: HER2-targeted therapies in CCA, US.
- 2020. Molecular targets/HER2-directed therapy. Conference. Molecular targets/HER2-directed therapy, US.
- 2020. Webcast: Advances in Next-Generation Sequencing-informed Precision Medicine. Conference. Webcast: Advances in Next-Generation Sequencing-informed Precision Medicine, US.
- 2020. Implementing Precision Oncology in Advanced and Early Stage Disease. Visiting. George H. A. Clowes Visiting Professor of Surgery. Boston, MA, US.
- 2020. Evolving Actionable Targets. Conference. 18th Oncology Update: Advances and Controversies. Steamboat Springs, CO, US.
- 2020. Advances in Precision Oncology. Visiting. New Brunswick, NJ, US.
- 2019. In-Person Special Emphasis Panel: Novel Technology Tools to Facilitate Research Using Next Generation Patient-derived Cancer Models. Conference. Cancer Moonshot Initiatives. Rockville, MD, US.
- 2019. Poster discussion: Safety and efficacy of ZW25, a HER2-targeted bispecific antibody, in combination with chemotherapy in patients with locally advanced and/or metastatic HER2-expressing gastroesophageal cancer. Conference. Poster discussion: Safety and efficacy of ZW25, a HER2-targeted bispecific antibody, in combination with chemotherapy in patients with locally advanced and/or metastatic HER2-expressing gastroesophageal cancer. Boston, MA, US.
- 2019. Precision Oncology through Multiplex Testing for Antibody Drug Conjugate Targets. Conference. Precision Oncology through Multiplex Testing for Antibody Drug Conjugate Targets. Rockville, MD, US.
- 2019. NCI MATCH and COMBO MATCH. Conference. Individualizing Medicine Conference: Precision Cancer Care Through Immunotherapy and Genomics. Scottsdale, AZ, US.
- 2019. Precision Oncology. Visiting. Sparkman Endowed Lecture. Dallas, TX, US.
- 2019. TAS-120 in patients with advanced solid tumors bearing FGF/FGFR aberrations: A Phase I study. Conference. TAS-120 in patients with advanced solid tumors bearing FGF/FGFR aberrations: A Phase I study. Atlanta, GA, US.
- 2019. Precision oncology decision support. Conference. Precision oncology decision support. San Francisco, CA, US.
- 2019. Poster presentation: Single-agent activity of ZW25, a HER2 targeted bispecific antibody, in HER2-expressing gastroesophageal and other cancers. Conference. Poster presentation: Single-agent activity of ZW25, a HER2 targeted bispecific antibody, in HER2-expressing gastroesophageal and other cancers. Salt Lake, UT, US.
- 2019. Promising actionable biomarkers from phase I studies. Conference. Promising actionable biomarkers from phase I studies. Breckenridge, CO, US.
- 2018. Decision Support for Genomically Informed Therapy. Conference. Decision Support for Genomically Informed Therapy. Biddleford, ME, US.
- 2018. Moderator: Science Behind the News. Conference. Moderator: Science Behind the News. Orlando, FL, US.
- 2018. Moderator, Symposium 3: Breakthrough in Triple Negative Cancer. Conference. Moderator, Symposium 3: Breakthrough in Triple Negative Cancer, US.
- 2018. Novel Targets and Overview of Ongoing Clinical Trials. Conference. Novel Targets and Overview of Ongoing Clinical Trials.
- 2018. Opportunities for Biomarker Driven Trials in Breast Cancer. Conference. Society of Surgical Oncology. Chicago, IL, US.
- 2018. Keynote Presentation: Advances in Genomic Diagnostics and Therapeutics. Conference. Keynote Presentation: Advances in Genomic Diagnostics and Therapeutics. Steamboat Springs, CO, US.
- 2017. Precision Medicine in Surgical Oncology: What Every Surgeon Needs to Know. Conference. Precision Medicine in Surgical Oncology: What Every Surgeon Needs to Know. San Diego, CA, US.
- 2017. Developmental therapeutics in TNBC. Conference. Developmental therapeutics in TNBC. Hollywood, CA, US.
- 2017. Translational research and biomarker-driven clinical trials. Visiting. Ann Arbor Annual Student Leadership Weekend. Ann Arbor, MI, US.
- 2017. Oxidative phosphorylation as a target in triple negative breast cancer therapy. Conference. Oxidative phosphorylation as a target in triple negative breast cancer therapy. Washington, DC, US.
- 2017. Advanced Clinical Trial Design for Advanced Breast Cancer. Conference. Advanced Clinical Trial Design for Advanced Breast Cancer. Washington, DC, US.
- 2017. Precision Medicine: Hype or Hope?. Conference. Precision Medicine: Hype or Hope?. Las Vegas, NV, US.
- 2017. Emerging treatment options for metastatic breast cancer. Conference. Emerging treatment options for metastatic breast cancer. Steamboat Springs, CO, US.
- 2016. Keynote Address: Genomically informed medicine. Invited. Health Sciences Research Day,. Columbia, MO, US.
- 2016. Genomically informed medicine. Conference. Genomically informed medicine. Columbia, MO, US.
- 2016. Ductal carcinoma in situ- Risk factor lesion or cancer?. Conference. Ductal carcinoma in situ- Risk factor lesion or cancer?. Washington, DC, US.
- 2016. Clinical and applied genomics in breast cancer, in Plenary Updates: Personalized Medicine and Genetics. Conference. Clinical and applied genomics in breast cancer, in Plenary Updates: Personalized Medicine and Genetics, US.
- 2016. Informatics technology for cancer research: Identifying clinically actionable genomic alterations for cancer therapy. Conference. Informatics technology for cancer research: Identifying clinically actionable genomic alterations for cancer therapy. New Orleans, LA, US.
- 2016. Identifying clinically actionable genomic alterations for cancer therapy. Conference. Identifying clinically actionable genomic alterations for cancer therapy. New Orleans, LA, US.
- 2016. DCIS – Is it cancer? – Yes. Conference. DCIS – Is it cancer? – Yes. Dallas, TX, US.
- 2016. Setting the stage for gene expression profiling in clinical cancer management: The Breast Cancer Experience. Conference. Setting the stage for gene expression profiling in clinical cancer management: The Breast Cancer Experience. Boston, MA, US.
- 2016. Neoadjuvant breast cancer therapy. Visiting. Department of Surgery Grand Rounds. Cedar Rapids, IA, US.
- 2016. Optimizing genomically informed therapy. Visiting. Holden Cancer Center Grand Rounds. Cedar Rapids, IA, US.
- 2016. Next generation of Phase 1 drug development based on biomarker discovery. Conference. Next generation of Phase 1 drug development based on biomarker discovery. Steamboat Springs, CO, US.
- 2015. Making the transition to independence. Conference. Making the transition to independence. Boston, MA, US.
- 2015. Making the transition to independence. Conference. Making the transition to independence. Boston, MA, US.
- 2015. Panel Discussion, Demonstrating the value of personalized medicine in clinical practice. Conference. Panel Discussion, Demonstrating the value of personalized medicine in clinical practice. Washington, DC, US.
- 2015. Education regarding the use of personalized medicine throughout the health care continuum. Conference. Education regarding the use of personalized medicine throughout the health care continuum. Washington, DC, US.
- 2015. Genomically informed breast cancer therapy. Conference. Genomically informed breast cancer therapy. Chicago, IL, US.
- 2015. PMO Live: Fourth Annual Conference of the Global Biomarkers Consortium. Conference. PMO Live: Fourth Annual Conference of the Global Biomarkers Consortium. Chicago, IL, US.
- 2015. Keynote Presentation: The Impact of Molecular Biomarkers on Clinical Trials. Conference. Fourth Annual Conference of the Global Biomarkers Consortium. Seattle, WA, US.
- 2015. Keynote Speaker, The impact of molecular biomarkers on clinical trials. Conference. Keynote Speaker, The impact of molecular biomarkers on clinical trials. Seattle, WA, US.
- 2015. Moderator, Session "Adjuvant Therapies". Conference. Moderator, Session "Adjuvant Therapies". Orlando, FL, US.
- 2015. PI3 Kinase and Cancer. Conference. PI3 Kinase and Cancer. Las Vegas, NV, US.
- 2014. Somatic mutation testing and opportunities for clinical interventions. Conference. Somatic mutation testing and opportunities for clinical interventions. San Francisco, CA, US.
- 2014. Targeting PI3K/mTOR signaling for breast cancer therapy. Invited. Melodie Wilson Oldenburg Breast Cancer Symposium. Milwaukee, WI, US.
- 2014. Targeting mTOR in breast cancer. Conference. Targeting mTOR in breast cancer. Philadelphia, PA, US.
- 2014. Best of San Antonio and ASCO. Conference. Best of San Antonio and ASCO. Las Vegas, NV, US.
- 2014. Personalizing cancer therapy: From bench to bedside. Invited. Washington, DC, US.
- 2014. How to incorporate genomic analysis in the multidisciplinary assessment and management of the surgical oncology patient. Conference. How to incorporate genomic analysis in the multidisciplinary assessment and management of the surgical oncology patient. Phoenix, AZ, US.
- 2014. Keynote Presentation: Molecular prognostic and predictive markers: Is personalized therapy around the corner?. Conference. Keynote Presentation: Molecular prognostic and predictive markers: Is personalized therapy around the corner?. Steamboat Springs, CO, US.
- 2014. Selective use of adjuvant therapy: Have the new markers helped?. Conference. Selective use of adjuvant therapy: Have the new markers helped?. Steamboat Springs, CO, US.
- 2013. Personalizing Cancer Therapy: Opportunities and Challenges. Invited. Breast Service Conference. New York, NY, US.
- 2013. Targeting PI3K-mTOR signaling. Invited. Surgical Research Conference. New York, NY, US.
- 2013. Best of San Antonio and ASCO Meetings. Conference. The American Society of Breast Surgeons 14th Annual Meeting. Chicago, IL, US.
- 2013. Nodal Staging and Management for Breast Cancer. Visiting. Madison, WI, US.
- 2013. CanDrA: Cancer-specific driver missense mutation annotation with optimized features. Conference. AACR Annual Meeting. Washington, DC, US.
- 2013. mTOR inhibitor MLN0128 has antitumor efficacy in cell lines with intrinsic and acquired rapamycin resistance in vitro and in vivo. Conference. AACR Annual Meeting. Washington, DC, US.
- 2013. Epithelial to mesenchymal transition and rapamycin sensitivity in cancer cell lines. Conference. AACR Annual Meeting. Washington, DC, US.
- 2013. Personalized Medicine from the Surgeons Perspective. Conference. 66th Annual Cancer Symposium. National Harbor, MD, US.
- 2013. Incidence and consequence of close margins for ductal carcinoma in situ treated with mastectomy. Conference. 66th Annual Cancer Symposium. National Harbor, MD, US.
- 2013. Utility of sentinel lymph node dissection (SLND) in ductal carcinoma in situ (DCIS). Conference. 66th Annual Cancer Symposium. National Harbor, MD, US.
- 2013. How do I develop a research focus?. Conference. How do I develop a research focus?. New Orleans, LA, US.
- 2012. Effect of Biospecimen Variables on Proteomic Biomarker Assessment in Breast Cancer. Conference. Effect of Biospecimen Variables on Proteomic Biomarker Assessment in Breast Cancer. San Antonio, US.
- 2012. Challenges and Opportunities for Personalized Cancer Therapy. Visiting. Grand Rounds. Los Angeles, CA, US.
- 2012. Molecular Characterization of Cancer Patients to Accelerate Personalized Medicine: MD Anderson Cancer Center Case Study. Conference. 4th Molecular Diagnostics for Cancer Drug Development. Boston, MA, US.
- 2012. Personalized Cancer Therapy: Opportunities and Challenges. Visiting. The Levine Lecture. Boston, MA, US.
- 2012. Biomarker Assessment for PI3K/mTOR-Targeted Breast Cancer Therapy. Conference. 65th Annual Cancer Symposium. Orlando, FL, US.
- 2012. Prophylactic Mastectomy. Conference. Prophylactic Mastectomy. Steamboat Springs, CO, US.
- 2012. Biomarkers: Prognostic or Predictive?. Conference. 10th Oncology Update: Advances and Controversies. Steamboat Springs, CO, US.
- 2011. Re-expression of ERalpha in ER Negative Breast Cancer Cells Following Trastuzumab Treatment. Conference. Re-expression of ERalpha in ER Negative Breast Cancer Cells Following Trastuzumab Treatment. San Francisco, CA, US.
- 2011. Targeting BRAFV600E using Nanoliposomal-Small Interfering RNA restores the Expression of Sodium Iodide Symporter and Increases the Uptake of Iodide in Thyroid Cancer Cells. Conference. Targeting BRAFV600E using Nanoliposomal-Small Interfering RNA restores the Expression of Sodium Iodide Symporter and Increases the Uptake of Iodide in Thyroid Cancer Cells. San Francisco, CA, US.
- 2011. The I-Domain, A Multifaceted Nanoparticle for Targeting of Poorly Differentiated Thyroid Cancer. Conference. The I-Domain, A Multifaceted Nanoparticle for Targeting of Poorly Differentiated Thyroid Cancer. San Francisco, CA, US.
- 2011. Imatinib Modulates Tumor Associated Macrophages in Gastrointestinal Stromal Tumor (GIST). Conference. Imatinib Modulates Tumor Associated Macrophages in Gastrointestinal Stromal Tumor (GIST). San Francisco, CA, US.
- 2011. Personalized Cancer Therapy: Promises and Challenges. Conference. Personalized Cancer Therapy: Promises and Challenges. Houston, TX, US.
- 2009. Targeting the mTOR Signaling Network for Cancer Therapy. Visiting. Atlanta, GA, US.
- 2009. Inflamatory Breast Cancer. Conference. 10th Annual Meeting ASBS. San Diego, CA, US.
- 2008. Are There Patients Who Should Not Receive Pre-Operative Therapy?. Conference. 2008 Breast Cancer Symposium. Washington, DC, US.
- 2008. Fellows, Residents, Trainees, and Junior Faculty Breakfast. Conference. 2008 Breast Cancer Symposium. Washington, DC, US.
- 2008. Future Directions in Therapy. Conference. 23rd Aspen Cancer Conference: Mechanisms of Toxicity, Carcinogenesis, Cancer Prevention and Cancer Therapy. Aspen, CO, US.
- 2008. ACOSOG CRA Training - Z1041 protocol. Conference. ACOSOG Annual Meeting 2008. Chicago, IL, US.
- 2007. Targeting Translation Initiation for Cancer Therapy. Conference. American College of Surgeons. New Orleans, LA, US.
- 2007. Surgical Update on Sentinel Lymph Node Assessment, Prophylactic Mastectomy and Immediate Reconstruction. Conference. 3rd U.T. M. D. Anderson Cancer Center & M. D. Anderson Physicians Network Annual Symposium. Santa Barbara, CA, US.
- 2007. Breast Conservation in Early and Advanced Disease. Conference. 3rd U.T. M. D. Anderson Cancer Center & M. D. Anderson Physicians Network Annual Symposium. Santa Barbara, CA, US.
- 2007. Establishing a Funded and Productive Laboratory (Meet The Professor Breakfast). Conference. 60th Annual Cancer Symposium. Washington, DC, US.
- 2007. Controversies in the Surgical Management of LCIS. Conference. 7th Annual Oncology Update: Advances and Controversies. Steamboat Springs, CO, US.
- 2006. Lumpectomy following Neoadjuvant Therapy: Technical Issues. Conference. American Society for Breast Surgeons Annual Conference. Baltimore, MD, US.
- 2006. Profiling in Patients with Breast Cancer. Conference. 6th Annual Oncology Update: Advances and Controversies. Park City, UT, US.
- 2005. Signal Transduction and Translational Regulation. Conference. TX/UK Collaborative Research Initiative Post Receptor Events in Cell Signaling and Disease Workshop. Scotland, TX, US.
- 2005. Treatment of DCIS. Conference. The U T M. D. Anderson Cancer Center and the M. D. Anderson Physicians Network First Annual Symposium: Breast and Prostate Cancer Update. Kauai, HI, US.
- 2004. Sentinel Lymph Node Mapping: Concepts and Controversies. Conference. The Radiology Society of North America. Chicago, IL, US.
- 2004. Surgical Therapy of Breast Cancer. Conference. American College of Surgeons. Washington, DC, US.
- 2003. Surgical Therapy of Breast Cancer: Challenges and Controversies. Conference. Korea Breast Cancer Society. Seoul.
Formal Peers
- 2025. Navigating the NCI's Early Therapeutics Clinical Trials Network, US.
- 2018. Developmental Therapeutics in Triple Negative Breast Cancer (TNBC). Invited. Hershey, PA, US.
- 2018. Liquid Biopsies/ctDNA. Invited. Toronto, CA.
- 2016. Decision support for genomically informed therapy. Invited. Rockville, MD, US.
- 2014. Connecting Cancer Variants to Clinical Phenotypes. Invited. Sonoma, CA, US.
- 2014. From Clinical to Basic Research. Invited. Lima, PE.
- 2014. Molecular Biology of Breast Cancer. Invited. Lima, PE.
- 2014. Tools for personalized therapy: Strengths and limitations. Invited. Tucson, AZ, US.
- 2013. Personalizing Investigational Cancer Therapeutics. Invited. Gilbert, AZ, US.
- 2013. Personalizing Breast Cancer Care: What have we achieved?. Invited. Toronto, CA.
- 2013. Targeting Pi3K/mTOR Signaling. Invited. Chicago, IL, US.
- 2012. Personalized Cancer Therapy: Opportunities and Challenges. Invited. Boston, MA, US.
- 2010. Managing the Extra-Axillary Sentinel Node and Positive Internal Mammary Node and Positive Internal Mammary Nodes. Invited. Boston, MA, US.
- 2010. Surgery Issues after Preoperative Therapy. Invited. Boston, MA, US.
- 2010. Personalizing Breast Cancer Therapy for Different breast phenotypes. Invited. Philadelphia, PA, US.
- 2010. Targeting mTOR for Breast Cancer Therapy. Invited. Philadelphia, PA, US.
- 2007. Principles of Molecular Therapeutics. Invited. Shijiazhuang, CN.
- 2007. Controversies in Sentinel Node Biopsy. Invited. Shijiazhuang, CN.
- 2006. The Role of Neoadjuvant Chemotherapy and Breast Surgery. Invited. Williamsburg, VA, US.
- 2006. Controversies in Breast Conservation. Invited. Williamsburg, VA, US.
- 2003. Targeting Translation Inhibition for Cancer Therapy. Invited. Seoul.
- 1998. Molecular Diagnosis of Cancer. Invited. Ann Arbor, MI, US.
- 1997. Regulation of Translation in Early Xenopus Development. Invited. Ann Arbor, MI, US.
- 1996. Translational Regulation in the Xenopus. Invited. Bethesda, MD, US.
- 1996. Masking of Maternal mRNA in Xenopus Laevis. Invited. Bethesda, MD, US.
Selected Publications
Peer-Reviewed Articles
- Wanis, K, Dong, W, Shen, Y, Meric-Bernstam, F, Adesoye, T, Kuerer, HM, Caudle, AS, Tamirisa, N, DeSnyder, SM, Sun, SX, Bedrosian, I, Singh, P, Cox, SE, Hunt, KK, Hwang, RF. Predicting pathologic ≥N2 disease in women with breast cancer. npj Breast Cancer 11(1), 2025. e-Pub 2025. PMID: 40404657.
- Meric-Bernstam, F, Rha, SY, Hamilton, E, Kang, YK, Hanna, D, Iqbal, S, Lee, KW, Lee, J, Beeram, M, Oh, DY, Chaves, J, Goodwin, RA, Ajani, JA, Yang, L, Oza, R, Elimova, E. Zanidatamab monotherapy or combined with chemotherapy in HER2-expressing gastroesophageal adenocarcinoma. Nature communications 16(1), 2025. e-Pub 2025. PMID: 40341383.
- Kettner, NM, Bui, T, Navarro-Yepes, J, Ghotbaldini, S, Quintela, B, Luo, CK, Lam, N, Rao, X, Singareeka Raghavendra, A, Wang, Y, Azizian, NG, Kris Eckols, T, Kasembeli, MM, Evans, KW, Yi, M, Wingate, H, Wang, J, Sahin, AA, Meric-Bernstam, F, Hunt, KK, Damodaran, S, Tweardy, D, Tripathy, D, Keyomarsi, K. IL-6 predicts CDK4/6 inhibitor resistance, identifying STAT3 as a target in HR + /HER2-negative metastatic breast cancer. npj Precision Oncology 9(1), 2025. e-Pub 2025. PMID: 40715551.
- Kushnarev, V, Stupichev, D, Davitavyan, S, Kriukov, K, Shanthappa, BU, Butusova, A, Menshikova, S, Belozerova, A, Shvyrkova, A, Tkachuk, A, Khatenkova, O, Balabanian, L, Postovalova, E, Lennerz, JK, Meric-Bernstam, F, Bagaev, A. RNA sequencing and immunohistochemistry jointly improve tumor biomarker interpretation. Scientific reports 15(1), 2025. e-Pub 2025. PMID: 40753302.
- Piha-Paul, SA, Tseng, C, Tran, HT, Fu, SC, Dumbrava, EE, Yap, TA, Naing, A, Lim, J, Murphy, MB, Ramirez, DL, Soliman, PT, Sood, AK, Meric-Bernstam, F. Phase I trial of neratinib plus palbociclib in advanced cancers with HER family alterations. ESMO Open 10(12), 2025. e-Pub 2025. PMID: 41223631.
- Azhar, M, Soto, F, Su, A, Gonzalez, NV, Medina, KB, Madrigal, AL, Duran, CC, Reyna, CR, Chan, C, Shroff, G, Bassett Jr, R, Pasyar, S, Zhang, D, Shannon, VR, Altan, M, Mitchell, MP, Meric-Bernstam, F, Mouabbi, JA, Murthy, RK, Faiz, S, Bashoura, L, Lim, B, Sheshadri, A. Incidence and risk factors for pneumonitis due to trastuzumab Deruxtecan in metastatic breast cancer. Breast Cancer Research 27(1), 2025. e-Pub 2025. PMID: 41194091.
- Ozirmak Lermi, N, Molina Ayala, M, Hernandez, S, Lu, W, Khan, KB, Serrano, A, Lubo Julio, IC, Hamana Zorrilla, L, Tomczak, K, Barnes, S, Dou, J, Liang, Q, Zhang, S, Zhang, Q, Zhang, J, Xu, M, Woodman, SE, Wang, W, Virani, S, Sun, B, Subramanya, S, Song, X, Shaw, KR, Prabhakaran, S, Piubelli, ML, Mohammad, MM, Meric-Bernstam, F, Mendoza, MT, Mallampati, S, Little, L, Lang, W, Knafl, M, Khanduri, I, Gite, S, Arrechedera, C, Raso, G, Tang, X, Sanchez Espiridion, B, Weissferdt, A, Heymach, JV, Zhang, J, Sepesi, B, Cascone, T, Tsao, A, Altan, M, Mehran, RJ, Gibbons, DL, Wistuba, II, Haymaker, CL, Chen, K. Comparison of imaging based single-cell resolution spatial transcriptomics profiling platforms using formalin-fixed paraffin-embedded tumor samples. Nature communications 16(1), 2025. e-Pub 2025. PMID: 41006245.
- Sledge, GW, Xiu, J, Mahtani, R, Sandoval-Leon, A, Meric-Bernstam, F, Ribeiro, JR, Kulkarni, NN, Rampa, DR, Lee, J, Ueno, NT, Oberley, MJ, Radovich, M, Spetzler, D. Mechanisms of resistance to trastuzumab deruxtecan in breast cancer elucidated by multi-omic molecular profiling. npj Breast Cancer 12(1), 2025. e-Pub 2025. PMID: 41422323.
- Msaouel, P, Tannir, NM, Meric-Bernstam, F, King, JM, Voss, MH, Cheng, JP, Thomas, SS, Lim, ZD, Karki, M, He, R, Genovese, G, Sheth, RA, Ingram, D, Shamsutdinova, D, Wani, K, Wang, W, Lazar, A, Knipper-Davis, D, Berlinski, A, Soares, T, Stupichev, D, Kryukov, K, Davitavyan, S, Novokreshchenova, A, Lebedev, D, Kurpe, S, Kravets, A, Belousov, D, Hensley, M, Bagaev, A, Paradiso, F, Kushnarev, V. Identification of therapeutic targets for renal medullary carcinoma via integrated genomic and transcriptomic profiling. Cell Reports Medicine 6(11), 2025. e-Pub 2025. PMID: 41172996.
- Wotman, MT, Khalaf, A, Wang, K, Meric-Bernstam, F, Gillison, M, Akhave, NS, Kerrigan, KC, Ferrarotto, R. Trastuzumab Deruxtecan in HER2-Low or HER2-Mutant Recurrent/Metastatic Secretory Gland Cancers of the Head and Neck. JNCCN Journal of the National Comprehensive Cancer Network 24(2), 2025. e-Pub 2025. PMID: 41213241.
- Swanton, C, Madison, RW, Tambaoan, CB, Meric-Bernstam, F, Sweeney, CJ, Kurzrock, R, Burris, H, Spigel, D, Tukachinsky, H, Hughes, JD, Malato, J, Yoo, B, Szado, T, Schwab, C, Pasquina, LW, Gasco, A, Schulze, K, Friedman, C. Circulating tumor DNA monitoring and blood tumor mutational burden in patients with metastatic solid tumors treated with atezolizumab. Molecular oncology 19(11):3060-3078, 2025. e-Pub 2025. PMID: 40434907.
- Gouda, M, Janku, F, Yuan, Y, Drusbosky, L, Chen, A, Zheng, X, Patel, KP, Hamilton, SR, Routbort, MJ, Tricoli, JV, Williams, PM, Iafrate, AJ, Sklar, J, Coffey, B, Little, R, Arteaga, CL, O'Dwyer, PJ, Flaherty, KT, Harris, LN, Meric-Bernstam, F. Concordance between Tumor Tissue and Plasma DNA Genotyping in the NCI-MATCH Trial (EAY131). Clinical Cancer Research 31(20):4299-4310, 2025. e-Pub 2025. PMID: 40388547.
- Varadarajan, K, Cruz Pico, CX, Evans, KW, Raso, G, Rizvi, YQ, Zheng, X, Chachad, D, DiPeri, TP, Wang, B, Scott, S, Zhao, M, Akcakanat, A, Wengner, AM, Yap, TA, Meric-Bernstam, F. Efficacy of ATR Kinase Inhibitor Elimusertib Monotherapy or Combination in Tumors with DNA Damage Response Pathway and Other Genomic Alterations. Molecular cancer therapeutics 24(9):1402-1414, 2025. e-Pub 2025. PMID: 40300249.
- Khatri, U, Dayal, N, Owusu, KB, Hunjan, MK, Pandey, S, Harper, HA, McMahan, C, Elzey, BD, Shen, T, Hu, X, Evans, KW, El-Sheikh, A, Jo, Sj, Holtsberg, FW, Aman, MJ, Meric-Bernstam, F, Woo, S, Sintim, HO, Wu, J. Identification of alkynyl nicotinamide HSN748 as a RET solvent-front mutant inhibitor with intracranial efficacy. MedChemComm 16(8):3541-3550, 2025. e-Pub 2025. PMID: 40496186.
- Janku, F, Jegede, O, Puhalla, S, Konstantinopoulos, PA, Meric-Bernstam, F, Zwiebel, J, Gray, R, Wang, V, McShane, LM, Rubinstein, L, Patton, DR, Williams, PM, Hamilton, SR, Takebe, N, Ghani, S, Tricoli, JV, Conley, BA, Arteaga, CL, Harris, LN, O'Dwyer, PJ, Chen, A, Flaherty, KT. PIK3CB Inhibitor GSK2636771 in Cancers With PTEN Mutation/Deletion or Loss of PTEN Protein Expression. JCO Precision Oncology 9, 2025. e-Pub 2025. PMID: 40865033.
- Derbala, M, Hajjar, J, Stephen, B, Gurses, S, Kwiatkowski, E, Budde, P, Zucht, HD, Bräutigam, M, Lindemann, AS, Abhari, BA, Gouda, M, Castillo, L, Zarifa, A, How, JA, Rodriguez, E, Moyers, JT, Hong, DS, Fu, S, Meric-Bernstam, F, Naing, A. Autoantibody profiling to predict response to the anti-PD-1 therapy, pembrolizumab, in rare tumors. ESMO Open 10(8), 2025. e-Pub 2025. PMID: 40768895.
- Meric-Bernstam, F, Raghav, KS, Sweeney, CJ, Swanton, C, Spigel, D, Bose, R, Burris, H, Friedman, C, Espenschied, CR, Grindheim, J, Malato, J, Schulze, K, Price, R, Kurzrock, R. ctDNA Analysis in ERBB2-Amplified Colorectal Cancer. Clinical Cancer Research 31(14):2935-2944, 2025. e-Pub 2025. PMID: 40512191.
- Chen, MK, Yamaguchi, H, Gao, Y, Xia, W, Chang, J, Hsiao, YC, Shegute, TW, Lin, ZS, Wu, CS, Wang, YH, Litton, J, Ding, Q, Wei, Y, Chu, Y, Meric-Bernstam, F, Piwnica-Worms, H, Arun, BK, Ahnert, JR, Liu, J, Yao, J, Chang, W, Wang, HL, Tapia, C, Albarracin, C, Keyomarsi, K, Wang, SC, Wang, Y, Hortobagyi, GN, Lin, C, Yang, L, Yu, D, Hung, M. FGFR3-induced Y158 PARP1 phosphorylation promotes PARP inhibitor resistance via BRG1/MRE11-mediated DNA repair in breast cancer models. Journal of Clinical Investigation 135(14), 2025. e-Pub 2025. PMID: 40460005.
- Al Baghdadi, T, Rothe, M, Mangat, PK, Garrett-Mayer, E, Crysler, OV, Mileham, KF, Farrington, LC, Adesunloye, B, Dublis, SA, Astsaturov, I, Calfa, C, Bleeker, J, Khalil, M, Thota, R, Cannon, TL, Alese, OB, Gold, PJ, Hafez, N, Baron, AD, Meric-Bernstam, F, Hobbs, EA, Marr, A, Rueter, J, Tawfik, B, Hinshaw, DC, Gregory, A, Grantham, GN, Halabi, S, Schilsky, RL. Olaparib in Patients With Solid Tumors With BRCA1/2 Alterations. JCO Precision Oncology 9, 2025. e-Pub 2025. PMID: 41100773.
- Jacomina, LE, Swanson, DM, Mitchell, MP, Woodward, W, Smith, B, Hoffman, K, Goodman, C, Garber, HR, Sun, SX, Yap, TA, Meric-Bernstam, F, Arzu, I, Bloom, ES, Schlembach, PJ, Strom, EA, Stauder, MC, Shaitelman, SF. Outcomes After Palliative Radiation Therapy in Patients With Symptomatic Locoregionally Advanced Breast Cancer. International Journal of Radiation Oncology Biology Physics 122(2):278-291, 2025. e-Pub 2025. PMID: 39549757.
- Westphalen, CB, Boscolo Bielo, L, Aftimos, P, Beltran, H, Benary, M, Chakravarty, D, Collienne, M, Dienstmann, R, El Helali, A, Gainor, J, Horak, P, Le Tourneau, C, Marchiò, C, Massard, C, Meric-Bernstam, F, Pauli, C, Pruneri, G, Roitberg, F, Russnes, HE, Solit, DB, Starling, N, Subbiah, V, Tamborero, D, Tarazona, N, Turnbull, C, van de Haar, J, Andre, F, Mateo, J, Curigliano, G. ESMO Precision Oncology Working Group recommendations on the structure and quality indicators for molecular tumour boards in clinical practice. Annals of Oncology 36(6):614-625, 2025. e-Pub 2025. PMID: 40194904.
- Ronaghy, A, Crimini, E, Holla, V, Mills Shaw, KR, Doefler, AM, Campbell, E, Yang, RK, Iorgulescu, JB, Patel, KP, McPherson, DD, Ning, J, Meric-Bernstam, F, Karp, DD. Clinical outcomes of tumor-agnostic targeting of BRAF, tumor mutation burden-high, and RET. ESMO Open 10(6), 2025. e-Pub 2025. PMID: 40460677.
- Wanis, K, Mitchell, MP, Giordano, SH, Litton, J, Shaitelman, SF, Tamirisa, N, Bedrosian, I, Dong, W, Shen, Y, Hunt, KK, Singh, P, Sun, SX, Caudle, AS, Kuerer, HM, Meric-Bernstam, F, Hwang, RF, Adesoye, T. Implications of omitting sentinel lymph node biopsy on adjuvant decision making for patients with small breast cancers. Cancer 131(11), 2025. e-Pub 2025. PMID: 40433858.
- Oaknin, A, Lee, JY, Makker, V, Oh, DY, Banerjee, S, Gonzalez-Martin, A, Jung, KH, Lugowska, I, Manso, L, Manzano, A, Melichar, B, Siena, S, Stroiakovski, D, Fielding, A, Puvvada, S, Smith, A, Meric-Bernstam, F. Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status: Post Hoc Analysis of DESTINY-PanTumor02. Advances in Therapy 42(5):2015-2018, 2025. e-Pub 2025. PMID: 40048102.
- Gouda, MA, Voss, MH, Tawbi, H, Gordon, MS, Tykodi, SS, Lam, ET, Vaishampayan, U, Tannir, NM, Chaves, J, Nikolinakos, P, Fan, AC, Lee, RJ, McDermott, DF, Shapiro, GI, Gandhi, L, Bhatia, S, Katragadda, V, Meric-Bernstam, F. A phase I/II study of the safety and efficacy of telaglenastat (CB-839) in combination with nivolumab in patients with metastatic melanoma, renal cell carcinoma, and non-small-cell lung cancer. ESMO Open 10(5), 2025. e-Pub 2025. PMID: 40359708.
- Abdou, Y, Barlow, WE, Gralow, J, Meric-Bernstam, F, Albain, KS, Hayes, DF, Lin, NU, Perez, EA, Goldstein, LJ, Chia, S, Dhesy-Thind, S, Rastogi, P, Alba, E, Delaloge, S, Schott, AF, Shak, S, Sharma, P, Lew, DL, Miao, J, Unger, JM, Tripathy, D, Hortobagyi, GN, Pusztai, L, Kalinsky, K. Race and clinical outcomes in hormone receptor-positive, HER2-negative, node-positive breast cancer in the randomized RxPONDER trial. Journal of the National Cancer Institute 117(5):889-897, 2025. e-Pub 2025. PMID: 39656951.
- Goyal, L, DiToro, DF, Hollebecque, A, Bridgewater, J, Shimura, M, Kano, A, Okamura, S, Silhavy, JL, Wacheck, V, Halim, AB, Meric-Bernstam, F. Genomic correlates of response and resistance to the irreversible FGFR1-4 inhibitor futibatinib based on biopsy and circulating tumor DNA profiling. Annals of Oncology 36(4):414-425, 2025. e-Pub 2025. PMID: 39672383.
- Gouda, MA, Gonugunta, A, Ileana Dumbrava, EE, Yap, TA, Rodon Ahnert, J, Piha-Paul, SA, Pohlmann, PR, Damodaran, S, Murthy, RK, Valero, V, Mouabbi, JA, Tripathy, D, Sahin, AA, Chen, H, Meric-Bernstam, F. Human Epidermal Growth Factor Receptor 2 Loss following Treatment with Trastuzumab Deruxtecan in Patients with Metastatic Breast Cancer. Clinical Cancer Research 31(7):1268-1274, 2025. e-Pub 2025. PMID: 39841861.
- Ahmed, J, Knisely, A, Torrado, C, Stephen, B, Yang, Y, Song, J, Alshawa, A, Zarifa, A, Jhingran, A, Koay, EJ, Morris, VK, Javle, M, Wolff, RA, Meric-Bernstam, F, Pant, S, Rodon Ahnert, J, Naing, A. A phase I/II trial of avelumab combinations with ivuxolimab, utomilumab, and radiation therapy in patients with advanced gastrointestinal malignancies. Oncologist 30(3), 2025. e-Pub 2025. PMID: 40139261.
- Ahmed, J, Stephen, B, Khawaja, MR, Yang, Y, Salih, I, Barrientos Toro, E, Raso, G, Karp, DD, Piha-Paul, SA, Sood, AK, Ng, CS, Johnson, A, Soliman, PT, Meric-Bernstam, F, Lu, KH, Naing, A. A phase I study of temsirolimus in combination with metformin in patients with advanced or recurrent endometrial cancer. Gynecologic oncology 193:73-80, 2025. e-Pub 2025. PMID: 39787747.
- Ahmed, J, Janku, F, Karp, DD, Piha-Paul, SA, Tsimberidou, AM, Yap, TA, Stephen, B, Yang, Y, Gurses, S, Liu, Q, Song, J, Meric-Bernstam, F, Naing, A. A phase 2 basket study of talabostat, a small-molecule inhibitor of dipeptidyl peptidases, administered in combination with pembrolizumab in patients with advanced solid cancers. Cancer 131(3), 2025. e-Pub 2025. PMID: 39853679.
- Piha-Paul, SA, Tseng, C, Tran, HT, Naing, A, Dumbrava, EE, Karp, DD, Rodon Ahnert, J, Yap, TA, Raghav, KS, Damodaran, S, Le, X, Soliman, PT, Lim, J, Meric-Bernstam, F. Phase I trial of the combination of the pan-ErbB inhibitor neratinib and mTOR inhibitor everolimus in advanced cancer patients with ErbB family gene alterations. ESMO Open 10(2), 2025. e-Pub 2025. PMID: 39908697.
- Gouda, MA, Zarifa, A, Yang, Y, Stephen, B, Gurses, S, Sprenger, A, Tian, Y, Derbala, M, Glitza, IC, Meric-Bernstam, F, Patel, SP. Selinexor (KPT-330) in Combination with Immune Checkpoint Inhibition in Uveal Melanoma. Journal of Immunotherapy and Precision Oncology 8(1):82-88, 2025. e-Pub 2025. PMID: 39816915.
- Meric-Bernstam, F, Yuca, E, Evans, KW, Zhao, M, Maejima, T, Karibe, T, Raso, G, Tang, X, Zheng, X, Rizvi, YQ, Akcakanat, A, Scott, S, Wang, B, Byers, LA, Tripathy, D, Okajima, D, Damodaran, S. Antitumor Activity and Biomarker Analysis for TROP2 Antibody–Drug Conjugate Datopotamab Deruxtecan in Patient-Derived Breast Cancer Xenograft Models. Clinical Cancer Research 31(3):573-587, 2025. e-Pub 2025. PMID: 39585341.
- Alhalabi, O, Gouda, MA, Milton, D, Momin, HA, Yilmaz, B, Stephen, B, Ejezie, CL, Moyers, JT, Gurses, S, How, JA, Fu, S, Rodon Ahnert, J, Hong, DS, Piha-Paul, SA, Subbiah, V, Elena Dumbrava, E, Karp, DD, Janku, F, Meric-Bernstam, F, Tannir, NM, Naing, A. A Phase IB Trial of Selinexor in Combination With Immune Checkpoint Blockade in Patients With Advanced Renal Cell Carcinoma. Cancer medicine 14(4), 2025. e-Pub 2025. PMID: 39945382.
- DiPeri, TP, Evans, KW, Scott, S, Zheng, X, Varadarajan, K, Kwong, L, Kahle, M, Cao, HS, Tzeng, CW, Vu, T, Kim, S, Su, F, Raso, G, Rizvi, YQ, Zhao, M, Wang, H, Lee, SS, Yap, TA, Rodon Ahnert, J, Javle, M, Meric-Bernstam, F. Utilizing Patient-Derived Xenografts to Model Precision Oncology for Biliary Tract Cancer. Clinical Cancer Research 31(2):387-402, 2025. e-Pub 2025. PMID: 39513959.
- Meric-Bernstam, F, Hollebecque, A, Furuse, J, Oh, DY, Bridgewater, J, Anderson, B, Hangai, N, Wacheck, V, Goyal, L. Plain language summary: an analysis of the safety of futibatinib treatment in people with different types of cancer. Future Oncology 21(2):139-150, 2025. e-Pub 2025. PMID: 39466121.
- Meric-Bernstam, F, Gutierrez, M, Sanz-Garcia, E, Villa, D, Zhang, J, Friedmann, J, Yan, F, Socinski, MA, Sarantopoulos, J, Raez, LE, Chu, QC, Chénard-Poirier, M, Chatterjee, M, Ren, H, Liu, Q, Levine, DA, Jhaveri, K. Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors. Cancer Research Communications 5(9):1664-1673, 2025. e-Pub 2025. PMID: 40762544.
- Xavier, CB, Andersen, C, Lim, J, Slade, JH, Bean, S, Kang, L, Le, H, Tsimberidou, AM, Naing, A, Hong, DS, Ileana Dumbrava, EE, Rodon Ahnert, J, Pohlmann, PR, Piha-Paul, SA, Champiat, S, Yap, TA, Tang, T, Meric-Bernstam, F, Fu, S. Modulating Treatment Outcomes of Patients with Solid Tumors in Immunotherapy Trials. Cancer Research Communications 5(9):1631-1641, 2025. e-Pub 2025. PMID: 40862547.
- Powles, T, Bhatia, A, Burtness, B, Kogawa, T, Nishina, T, Nakayama, I, Fountzilas, C, Castillo, DR, McKean, M, Meric-Bernstam, F, Colombo, N, Smithy, JW, Fayette, J, Chandra, S, Sternberg, DW, Jin, F, Sullivan, K, Yueh, S, Clinthorne, G, Aguilo, AE, Kudchadkar, RR, Hayashi, H. HERTHENA-PanTumor01. Future Oncology 21(25):3283-3292, 2025. e-Pub 2025. PMID: 41088723.
Invited Articles
- Meric-Bernstam F. The need for Molecular Tumour Boards. Nature Medicine, 2025. e-Pub 2025.
Review Articles
- Sahin, AA, Chen, H, Xiao, H, Damodaran, S, Meric-Bernstam, F. Emerging molecular Therapeutic targets in breast Cancer. Human Pathology 162, 2025. e-Pub 2025. PMID: 40759284.
- Shah, NM, Meric-Bernstam, F. The present and future of precision oncology and tumor-agnostic therapeutic approaches. Oncologist 30(6), 2025. e-Pub 2025. PMID: 40536268.
- Meric-Bernstam, F, Bardia, A, Bossi, P, Bianchini, G, Gatlin, F, Lalla, RV, Melosky, B, Niikura, N, Yap, TA, Kim, SS, Rajagopalan, R, Fairhurst, RM, Graff, SL, Rugo, H. Prophylaxis, clinical management, and monitoring of datopotamab deruxtecan-associated oral mucositis/stomatitis. Oncologist 30(3), 2025. PMID: 40139260.
Abstracts
- Bedard PL, S-A I, Elimova E, Rha SY, Goodwin RA, Ferrario C, K-W L, Martynova A, Meric-Bernstam F, Kabos P, Beeram M, Hamilton EP, Cobleigh M, Samuel Nached T, Sharma K, D-Y O. Zanidatamab (Zani) + chemotherapy (Chemo) for patients (Pts) with HER2-expressing metastatic breast cancer (mBC): Final results of a phase I trial. ESMO Breast Cancer Congress, 2025. e-Pub 2025.
- Hamilton EP, Han H, Abuhadra N, Kalinsky K, McAndrew NP, Spira A, Chan N, Kelley K, Parajuli R, O'Shaughnessy J, Starks D, Wulf G, Weise AM, Chaudhry A, Wang JS, Richardson DL, Meric-Bernstam F, Burger R, Bradshaw C, Giordano A. Clinical activity of emiltatug ledadotin (Emi-Le), a B7-H4-directed ADC, in patients with TNBC who received at least one prior topoisomerase-1 inhibitor (Topo-1) ADC. ESMO Breast Cancer Congres, 2025. e-Pub 2025.
- Baird RD, W-P C, Schmid P, Dongen MV, Jung KH, Naito Y, Shimoi T, Lau PKH, Meric-Bernstam F, D-Y O, Rubovszky G, Van Gorp T, Aftimos P, Lugowska I, Sanai E, Dubois VFS, MillerN, Varga A, Luheshi N, Kim GM. Puxitatug samrotecan (P-Sam, AZD8205) in patients (pts) with HR+/HER2– breast cancer (BC): A first-in-human phase I/IIa dose escalation and expansion study. ESMO Breast Cancer Congress, 2025. e-Pub 2025.
- Mouabbi AJ, Sakr Y, Singareeka Raghavendra A, Abualkhair OA, Barcenas CH, Damodaran S, Layman RM, Tripathy D, Pohlmann PR, Meric-Bernstam F. Real-world effectiveness of trastuzumab deruxtecan (T-DXd) in endocrine therapy (ET)-refractory metastatic invasive lobular carcinoma (mILC) with HER2-low wild type (HER2wt) versus HER2-low mutant (HER2m). ESMO Breast Cancer Congress, 2025. e-Pub 2025.
- Srour SA, Tannir N, Jazaeri A, Campbell MT, Nieto Y, Haymaker C, Yuan Y, Salih I, Yang Y, Doppler V, Garibal J, Escande M, Yang M, Kushner J, Koo J, Gurses SA, Hong DS, Fu S, Meric-Bernstam F, Naing A. Safety and efficacy of HLA-G-targeted CAR T cells (IVS-3001) in patients with advanced HLA-G-positive solid tumors: Clinical trial in progress. AACR Annual Meeting 85(8), 2025. e-Pub 2025.
- Nguyen TQA, McGrail DJ, Dai H, Cifci A, Du Y, Meric-Bernstam F, S-Y L. Targeting RNase H2: a dual mechanism strategy to elevate replication stress, DNA damage, and antitumor immunity in triple-negative breast cancer. AACR Annual Meeting 85(8), 2025. e-Pub 2025.
- Mouabbi JA, Hammell A, SuryawanshiS, Middleton L, Bassett R, Zaayman T, Geoffrey L, Meric-Bernstam F. REPLOT Trial: Phase II study of repotrectinib with or without fulvestrant in patients with HR+ HER2- metastatic invasive lobular carcinoma previously treated with endocrine therapy and CDK4/6 inhibition. AACR Annual Meeting 85(8), 2025. e-Pub 2025.
- Akhave N, Holder A, Davies M, Pacha O, Weiser R, Meric-Bernstam F, Naing A. Phase 2 study of Ivonescimab in patients with cutaneous squamous cell carcinoma. AACR Annual Meeting 85(8), 2025. e-Pub 2025.
- Torrado C, Tomczak K, Dumbrava EE, Sun B, Ngoi N, Arrechedera C, Para ER, Rodon Anhert J, Piha-Paul SA, Tsimberidou AM, Fu S, Naing A, Pohlmann PR, Hong DS, Meric-Bernstam F, Msaouel P, Haymaker CL, Yap TA. Clinical and translational study of the TGF-β monoclonal antibody SAR439459 in combination with the PD-1 inhibitor cemiplimab for patients (pts) with advanced solid tumors: Results from the phase 1b TACTIC trial. AACR Annual Meeting, 2025. e-Pub 2025.
- Jeong J, Ma J, Abed M, Chung H, Kim D, Molden N, Rajendran D, Shim C, Jandial DD, LacknerMR, Simpkins F, Meric-Bernstam F, Randall LM, Harismendy O. Cell-free DNA molecular response predicts clinical efficacy in HGSOC patients treated with azenosertib. AACR Annual Meeting 85(8), 2025. e-Pub 2025.
- George GC, Lee H, Piha-Paul SA, Dumbrava E, Tsimberidou A, Fu S, Appleton G, Noor L, Rodon J, Yap TA, Meric-Bernstam F, Hong DS. Food choices of patients with advanced cancer at start of early-phase combination trials with immune checkpoint blockade. AACR Annual Meeting 85(8), 2025. e-Pub 2025.
- Braganca Xavier C, Andersen C, Lim JT, Slade JH, Bean SA, Kang L, Le H, Tsimberidou A, Naing A, Hong D, Dumbrava E, Rodon J, Pohlmann P, Piha-Paul S, Champiat S, Yap TA, T-Y T, Meric-Bernstam F, Fu S. Modulating treatment outcomes of patients with solid tumors in immunotherapy trials: a drug interaction analysis from a phase I unit. AACR Annual Meeting 85(8), 2025. e-Pub 2025.
- Lei JT, Dobrolecki LE, Huang C, Srinivasan RR, Vasaikar SV, Lewis AN, Sallas C, Zhao N, Cao J, Landua JD, Moon CI, Liao Y, Hilsenbeck SG, Osborne CK, Rimawi MF, Ellis MJ, Petrosyan V, Wen B, Li K, Saltzman AB, Jain A, Malovannaya A, Wulf GM, Marangoni E, Li S, Kraushaar DC, Wang T, Damodaran S, Zheng X, Meric-Bernstam F, Echeverria GV, Anurag M, Chen X, Welm BE, Welm AL, Zhang B Lewis MT. Patient-derived xenografts allow deconvolution and prediction of chemotherapy responses. AACR Annual Meeting 85(8), 2025. e-Pub 2025.
- Gouda MA, Xavier CB, Torrado C, Shah PA, Rai K, Vokes N, Alhalabi O, Bedford MT, Gao J, Majd NK, Li J, Javle M, Meric-Bernstam F, Rodon J. Pan-cancer prevalence of unusual MTAP alterations: data from the AACR GENIE databas. AACR Annual Meeting 85(8), 2025. e-Pub 2025.
- Alkassis S, Lipsyc-Sharf M, Hegarty-Traverso C, Mercer J, Yilma B, Fragkogianni S, Yuan Y, Meric-Bernstam F, Rugo H, O'Shaughnessy J, Rimawi M, Schiff R, Elashoff D, Glaspy J, McDermott M, Cummings A, Chao C, Bardia A. Genomic and transcriptomic mediators of resistance to antibody-drug conjugates (ADCs) in metastatic breast cancer (MBC): A comprehensive multi-center study. AACR Annual Meeting 85(8), 2025. e-Pub 2025.
- Srkalovic G, Rothe M, Mangat PK, Garrett-Mayer E, Mileham KF, Adesunloye B, Colocci N, Chen MD, Meric-Bernstam F, Pisick E, Marr AS, Benyounes A, Alese OB, Gregory A, Hinshaw DC, Grantham GN, Halabi S, Schilsky RL. Sunitinib (S) in patients (pts) with solid tumors with FGFR2 alterations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. AACR Annual Meeting 85(8), 2025. e-Pub 2025.
- Ngoi NYL, Rodon J, Dumbrava EE, Garmezy B, Hong DS, Piha-Paul S, Tsimberidou AM, Fu S, Naing A, Pohlmann PR, T-Y T, Clemente H, Rhudy J, Valladolid C, Salguero C, Velez NA, Tran HT, Meric-Bernstam F, Yap TAA. TalaCom: Phase Ib investigator-initiated trial combining talazoparib and axitinib in patients with DNA damage response mutated cancers or BRCA1/2 wildtype ovarian cancer incorporating prospective intrapatient dose titration. ESMO Targeted Anticancer Therapies (TAT) Congress, 2025. e-Pub 2025.
- Stephen B, Kwiatkowski E, Anderson MR, Derbala MH, Salih I, Castillo L, Yang Y, Gurses SA, Lim JT, Klekers AR, Le H, Kang L, Xu M, Ahmed J, Tan HN, Champiat S, T-Y T, Dumbrava EE, Fu S, Piha-Paul SA, Rodon Ahnert J, Tsimberidou AM, Yap T, Yuan Y, Hong DS, Meric-Bernstam F, Bhosale P, Naing A. Impact of liver metastases and systemic biomarkers on immunotherapy response and survival outcomes in patients with solid tumors. AACR IO, 2025. e-Pub 2025.
- Meric-Bernstam F, Alhalbi O, Lisberg A, Drakaki A, Garmezy B, Kogawa T, Spira AI, Salkeni MA, Gao X, Tolcher AW, Bhave MA, Doroshow DB, Hoffman-Censits J, Klauss G, Kaga Y, Kakurai Y, Kojima T. Datopotamab deruxtecan (Dato-DXd) in locally advanced/metastatic urothelial cancer: Updated results from the phase 1 TROPIONPanTumor01 study. ASCO Genitourinary Cancers Symposium, 2025. e-Pub 2025.
- Trueman S, Wu L, Girgis S, Vaidya K, Meric-Bernstam F, Harding J, Pant S, Zhao Y, Garfin P, Iannone R, Zhou H, Ma J. Zanidatamab dose optimization in patients with HER2-positive biliary tract cancer (BTC). ASCO Gastrointestinal Cancers Symposium, 2025. e-Pub 2025.
- Lee C-K, Seo DH, Fox D, Haro-Silerio J, Chung T, Kim CG, Bhamidipati D, Meric-Bernstam F, Pant S, Javle M, Lee S. Impact of HER2-positivity on prognosis and targeted therapeutic outcomes in advanced biliary tract cancer. ASCO Gastrointestinal Cancers Symposium, 2025. e-Pub 2025.
Book Chapters
- Meric-Bernstam F. Incorporating precision medicine into Phase I clinical. In: Phase I Trials in Oncology. Springer, 2020.
- Carson III WE, Meric-Bernstam F, Pollock RE. Oncology. In: Schwartz's Principles of Surgery. Eleventh. McGraw-Hill, Chapter 10, 2019.
- Owusu-Brackett N, Shariati M, Meric-Bernstam F. Role of PI3k/AKT/mTOR in Cancer Signaling. In: Predictive Biomarkers in Oncology: Applications in Precision Medicine. Springer International Publishing AG (Springer Nature), 263-270, 2018.
- Owusu-Brackett N, Meric-Bernstam F. Ductal carcinoma in situ: risk factor or cancer. In: Atypical Breast Proliferative Lesions and Benign Breast Disease. Springer International Publishing, 37-49, 2018.
- Evans KW, Paez Arango N, Akcakanat A, Yuca E, and Meric-Bernstam F. Modeling breast cancer heterogeneity with patient-derived xenografts. In: Patient Derived Tumor Xenograft Models: Promise, Potential and Practice. Elsevier Inc, Chapter 4:243-256, 2017.
- Naing A, Mills GB, Meric-Bernstam F. P13K-mTor in Cancer and Cancer Therapy. In: Cancer Drug Discovery and Development. Springer, 151-180, 2016.
- Holder AM, Meric-Bernstam F. Toward Personalized Therapy for Cancer. In: Translational Cancer Therapeutics: Molecular Therapeutics. Wiley, 268 pp, 2015.
- Akay C, Meric-Bernstam F. Treatment of advanced breast cancer. In: Surgery: Core Principles and Practice. 2/e (Chapter 103). JP Medical Publishers, 2015.
- Meric-Bernstam F, Pollock RE. Oncology. In: Schwartz's Principles of Surgery. Tenth. McGraw-Hill, Inc, pp. 1069, 2014.
- McAuliffe PF, Strom E, Meric-Bernstam F. Feasibility of Breast Conservation Therapy. In: Advanced Therapy of Breast Disease 3rd Edition. People's Medical Publishing House, 877-894, 2012.
- Bernstam E, Meric-Bernstam F. Quality and accuracy of online health information. In: E-health: The advent of online cancer information systems. Hampton Press, 35-62, 2011.
- Meric-Bernstam F. Neoadjuvant Chemotherapy. In: Kuerer's Breast Surgical Oncology. McGraw-Hill, 885-894, 2010.
- Meric-Bernstam F, Pollock RE. Oncology. In: Schwartz's Principles of Surgery. Ninth. McGraw Hill, Inc, 235-69, 2009.
- Hunt KK, Meric-Bernstam F. Surgical Options For Breast Cancer. In: M. D. Anderson Cancer Care Series, Breast Cancer. Second. Springer Science & Business Media LLC, 197-234, 2008.
- Meric-Bernstam F. Molecular Underpinnings. In: Advanced Therapy in Surgical Oncology. BC Decker Inc, 6-24, 2008.
- Meric-Bernstam F, Symmans WF. Prognostic/Predictive Profiling in Breast Cancer. In: Advanced Therapy in Surgical Oncology. BC Decker Inc, 533-42, 2008.
- Meric-Bernstam, F, et al. Funda Meric-Bernstam, M.D. In: Legends and Legacies, Personal Journies of Women Physicians and Scientists at M.D. Anderson Cancer Center. Women Faculty Programs, Public Affairs and Scientific Publications, M.D. Anderson Cancer, 116-23, 2008.
- Meric-Bernstam F. M. D. Anderson Kanser Merkezi deneyimleri. In: Sentinel Lenf Nodu Biyopsisi. Istanbul Medikal Ltd. Sti, 169-82, 2007.
- Bernstam EV, Meric-Bernstam F. Reliability and evaluation of online health information. In: Web Mobile-Based Applications for Healthcare Management. Idea Group Press, 181-196, 2007.
- Andtbacka RH, Meric-Bernstam F, Robinson EK, Hunt KK. Noninvasive Breast Cancer. In: The M D Anderson Surgical Oncology Handbook. Fourth. Lippincott Williams and Wilkins, 1-22, 2006.
- Meric-Bernstam F, Pollock RE. Oncology. In: Schwartz's Manual of Surgery. Eighth. McGraw-Hill Inc, 183-215, 2006.
- Meric-Bernstam F, Pollock RE. Oncology. In: Principles of Surgery. Eighth. McGraw-Hill, Inc, 249-294, 2004.
- McAuliffe P, Strom EA, Meric-Bernstam F. Feasibility of Breast Conservation Surgery. In: Advanced Therapy of Breast Disease. BC Decker Inc, 509-521, 2004.
- Meric F, Robinson E, Hunt KK. Noninvasive Breast Cancer. In: The M. D. Anderson Surgical Oncology Handbook. Third. Lippincott Williams and Wilkins, 1-13, 2003.
- Meric F, Ross MI. Benign Breast Disease. In: Unbound Surgery. Unbound Medicine, 2002.
- Pusztai L, Symmans WF, Buchholz TA, Stec J, Ayers M, Clark E, Meric F, Stivers D, Hess K. Application of DNA Microarray Technology to Clinical Biopsies of Breast Cancer. In: Computational And Statistical Approaches To Genomics. Kulwer Academic Publishers, 257-276, 2002.
- Meric F, Ross MI. Breast Cancer. In: Unbound Surgery. Unbound Medicine, 2002.
- Meric F, Hunt KK. Surgical Options for Breast Cancer. In: M. D. Anderson Cancer Care Series, Breast Cancer. Springer-Verlag, 187-222, 2001.
Patient Reviews
CV information above last modified August 20, 2026